Journal of the American Academy of Child & Adolescent Psychiatry
Letter to the editorOffice Visits to Monitor Stimulant Medication Safety and Efficacy: Recommended Care
References (5)
- et al.
Relationship between attention-deficit/hyperactivity disorder care and medication continuity
J Am Acad Child Adolesc Psychiatry
(2016) - et al.
Specific components of pediatricians’ medication-related care predict attention-deficit/hyperactivity disorder symptom improvement
J Am Acad Child Adolesc Psychiatry
(2017)
Cited by (3)
Measurement-based Data to Monitor Quality: Why Specification at the Population Level Matter?
2020, Child and Adolescent Psychiatric Clinics of North AmericaCitation Excerpt :Although stimulant medication prescription persistence is poor in managed care Medicaid programs,18 this measure does not directly report the substantial proportion of children who do not receive ongoing stimulant medication treatment. Concerns about adequate medication safety monitoring have also been raised, given that a minimum of 1 follow-up visit and a telephone contact with a prescriber during a 9-month period is sufficient to pass, and this level of contact is inconsistent with federal rules for prescription of Schedule II drugs.68,69 For the follow-up after hospitalization for mental illness, the attribution problem is demonstrated.
U.S. Child Behavioral Health Quality Measures: Advancing a National Research Agenda
2020, Journal of Abnormal Child PsychologyNational Child Mental Health Quality Measures: Adherence Rates and Extent of Evidence for Clinical Validity
2019, Current Psychiatry Reports
This research was supported by the Behavioral Health Centers of Excellence for California (SB852).
Disclosure: Dr. Zima has received grant or research support from the Patient-Centered Outcomes Research Institute (PCORI), the Illinois Children’s Healthcare Foundation, the UCLA Clinical and Translational Science Institute, the California Department of Health Care Services, and the California Mental Health Services Act. She is deputy editor to the Journal of Child and Adolescent Psychopharmacology, consulting editor to the Journal of the American Academy of Child and Adolescent Psychiatry and the Journal of Clinical Child and Adolescent Psychology, guest co-editor to Ethnicity and Disease, and on the editorial board of the Journal of Emotional and Behavioral Disorders. She also has served on the editorial boards to Psychiatric Services and Academic Psychiatry. She has received honoraria from the National Institute of Mental Health review committee. Dr. Norquist is vice-chair of the Emory University Department of Psychiatry and Behavioral Sciences, chief of Psychiatry Service at Grady Health System in Atlanta, chair of the PCORI Board of Governors, and chair of the American Psychiatric Association Council on Quality Care. He also has been a member of several journal editorial boards, including Psychiatric Services, Archives of General Psychiatry, and Journal of Mental Health Policy and Economics. Dr. Behrens is a member on the Express Scripts Medical Advisory Board, CEO of Envision ADHD, and advisor to Alay Health. Drs. Altchuler, Iles-Shih, Ng, and Schaepper report no biomedical financial interests or potential conflicts of interest.
All statements expressed in this column are those of the authors and do not reflect the opinions of the Journal of the American Academy of Child and Adolescent Psychiatry. See the Instructions for Authors for information about the preparation and submission of Letters to the Editor.